FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Invion's Free Cash Flow for the
six
months ended in Dec. 2025 was $-0.86 Mil. Invion's Revenue for the
six
months ended in Dec. 2025 was $0.00 Mil. Therefore, Invion's FCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.
The historical rank and industry rank for Invion's FCF Margin % or its related term are showing as below:
During the past 13 years, the highest FCF Margin % of Invion was 95.80%. The lowest was -253.92%. And the median was -54.40%.
IVIXF's FCF Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.51 * Ranked among companies with meaningful FCF Margin % only.
Invion FCF Margin % Related Terms
Invion FCF Margin % Historical Data
* Premium members only.
The historical data trend for Invion's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Invion's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invion FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Invion's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Invion's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invion (IVIXF) has a FCF Margin % of 0.00% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Invion and its competitors. According to the industry distribution chart, Invion ranks #999999 out of 958 companies in the Drug Manufacturers industry.
Is Invion's FCF Margin % too high?
Invion's current FCF Margin % is 0.00%. Based on the distribution chart, Invion ranks #999999 out of 958 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Invion has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Invion's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Invion ranks #999999 out of 958 companies for FCF Margin %. This places Invion in the lower half of its industry. The industry median FCF Margin % is 2.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Invion and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invion's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invion stock overvalued right now?
Invion (IVIXF) has a current FCF Margin % of 0.00%. The stock's GF Value™ is $0.17, compared to a current price of $0.04 — trading 78.3% below its estimated fair value. The current FCF Margin % is 0.00%. Invion's overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Invion (IVIXF), the current FCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Invion (IVIXF) Overvalued in 2026?
Based on GuruFocus' analysis, Invion stock appears to be undervalued.
The current stock price of $0.04 is trading 78.3% below its estimated GF Value™ of $0.17.
Key valuation signals for IVIXF:
FCF Margin %: 0.00%
GF Value™: $0.17 vs. price of $0.04 (78.3% below fair value)
No single metric tells the full story. See the IVIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Invion Ltd is an Australian clinical-stage pharmaceutical drug development company. It is engaged in the development of PhotoDynamic Therapy (PDT) for cancer treatments called Photosoft, for the treatment of a range of cancers, and infectious diseases. The company produces topical and intravenous products suitable for use in skin cancer and solid tumors, such as ovarian, prostate, and lung cancer. Invion has developed a portfolio of patent protected compounds. Its drug candidate is INV043, a novel photosensitiser which has the potential to work as a therapy and a diagnostic tool.
16GF Score
Get the complete analysis for IVIXF
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVIXF has been successfully added to your 
